Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D018360:Crystallography, X-Ray; D004354:Drug Screening Assays, Antitumor; D006868:Hydrolysis; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D009682:Magnetic Resonance Spectroscopy; D015674:Mammary Neoplasms, Animal / Q000473:pathology; D020780:Matrix Metalloproteinase 9 / Q000737:chemistry; D051379:Mice; D015394:Molecular Structure; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis / Q000517:prevention & control*; D009942:Organometallic Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D012428:Ruthenium / Q000493:pharmacokinetics; D013056:Spectrophotometry, Ultraviolet; D013329:Structure-Activity Relationship; D014018:Tissue Distribution
D000970:Antineoplastic Agents; D009942:Organometallic Compounds; C483483:aquatrichloro(dimethylsulfoxide)(5,7-(1,2,4)triazolo(1,5-a)pyrimidine)ruthenium(III); C483482:tetrachloro(dimethylsulfoxide)(5,7-dimethyl(1,2,4)triazolo(1,5-a)pyrimidine)ruthernium(III); D012428:Ruthenium; D020780:Matrix Metalloproteinase 9